Life Sciences Ontario
Life Sciences Ontario (LSO) strives to be the unified Voice of Life Sciences in Ontario by representing the interests of the diverse life sciences community in the province through advocacy, education, facilitation of economic development and promotion of the industry locally, nationally and internationally. Together we are a strong, innovative sector with significant socioeconomic contributions to the province of Ontario. We hope you will consider joining LSO and help us to achieve our vision for Ontario's life sciences sector - "Diversity of Members, Unity of Voice".
Algae Dynamics Corp Announces Research Agreement With University Of Waterloo To Investigate Use Of Cannabis Oil In The Context Of Cancer
Friday, February 24, 2017
ALGAE DYNAMICS CORP (OTCQB:ADYNF) (the "Company"), a development stage company focused on the commercialization of its proprietary BioSilo(R) cultivation and extraction system for the growth of algae strains for use in the food and health supplement industry, today announced a research agreement with the University of Waterloo to perform fundamental research on cannabis oil and its constituents in the context of the development and treatment of cancers of the colorectum, pancreas, breast and prostate. The Sponsored Research Agreement is entitled Studies on botanical oils from Algae Dynamics.
Big Pharma: Getting away with murder, or saving lives?
Friday, February 3, 2017
Jason Field, Life Sciences Ontario President & CEO, on the dangerous myths putting Canadas pharmaceutical industry at risk
US President Donald Trump recently sent biotech stocks tumbling with his claim that the pharmaceutical industry is getting away with murder. In a meeting with major US pharma companies this week, he again slammed pricing, and said he wants to see more drug manufacturing return to the US.
PlantForm to receive Government of Canada funding to advance HIV antibody research
Wednesday, December 21, 2016
PlantForm Corporation is advancing its work on innovative antibody treatments for human immunodeficiency virus (HIV) with a financial contribution of up to $117,400 and technical and business advisory services from the National Research Council of Canada Industry Research Assistance Program (IRAP). It is the third round of funding PlantForm has received from IRAP for the HIV project since 2012, for a total financial contribution of up to $1,484,970.
Innovative Medicines Canada Welcomes Pamela Fralick as New President
Thursday, December 1, 2016
Innovative Medicines Canada is pleased to announce the appointment of Pamela Fralick as its new President, effective immediately.
Ms. Fralick comes to Innovative Medicines Canada as a proven healthcare leader, with a wealth of experience advancing critical healthcare initiatives and a deep understanding of public policy and organizational management.
Cyclica Receives the Healthcare and Life Sciences Award for Excellence in Life Saving Therapeutics 2016
Thursday, December 1, 2016
Cyclica, an in silico drug discovery company that offers a novel proteome-wide screening predictive analytics platform for the pharmaceutical and related industries, has been recognized by Corporate LiveWire Magazine in their 2016 Healthcare and Life Sciences Award series in the category of Excellence in Life Saving Therapeutics. The platform is being used and validated through third-party organizations to develop safer and more effective therapeutics. Whether hypothetical, pre-clinical, clinical, or FDA-approved, Cyclica offers proteome-wide insight and analysis into a small molecules effect augmenting drug discovery pipelines, and efficiently taking assets from bench-to-bedside.